Axsome's AXS-05 Helps Patients Quit Smoking Significantly in Phase II Trial

Axsome Therapeutics, based in New York City, announced that its AXS-05 met its primary endpoint for smoking cessation treatment. The drug significantly reduced daily smoking compared to patients on bupropion.